AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29741773
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with weekly carboplatin (AUC 2) and paclitaxel (135 mg/m2), plus daily lapatinib (1000 mg) for 6 weeks followed by surgical resection.
Trial: 29741773
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with weekly carboplatin and paclitaxel, plus daily lapatinib followed by surgical resection.
Trial: 29741773
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy and surgical resection followed by risk-adapted adjuvant therapy.
Trial: 29741773
Drug: Surgery following
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surgery following induction chemotherapy.
Trial: 24990099
Drug: rhAd5 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhAd5 injection
Trial: 24990099
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no gene therapy)
Trial: 12426859
Drug: Alpha1-adrenoceptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha1-adrenoceptor antagonists (alfuzosin, doxazosin, tamsulosin, terazosin)
Trial: 12426859
Drug: Alpha1-adrenoceptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha1-adrenoceptor antagonists
Trial: 12426859
Drug: Alpha1-blockers
RxNorm normalized name: Thymosin alpha1 (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha1-blockers
Trial: 8537548
Drug: Low-dose recombinant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose recombinant human tissue plasminogen activator (rhtPA: 10 mg)
Trial: 1691406
Drug: quinapril, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quinapril, 5 mg twice daily (b.i.d.)
Trial: 1691406
Drug: quinapril, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quinapril, 10 mg b.i.d.
Trial: 1691406
Drug: quinapril, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quinapril, 20 mg b.i.d.
Trial: 1691406
Drug: quinapril (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quinapril (dosage titrated to a maximum of 40 mg/day, 20 mg b.i.d.)
Trial: 31270177
Drug: Standard Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Oxygen Therapy (standard O2)
Trial: 18410297
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg/day for the first week, then 40 mg/day for the following 3 weeks)
Trial: 16952654
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (100% O2 at 2.4 atmosphere absolute for 30 sessions)
Trial: 16952654
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (1.3 atmosphere absolute, breathing normal air)
Trial: 11125653
Drug: Multimedia form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimedia form administered by computer
Trial: 11125653
Drug: Written form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Written form administered by computer (computerized page-turner)
Trial: 3884426
Drug: Ranitidine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (0.3 g/day in 2 oral doses)
Trial: 3884426
Drug: Cimetidine (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1.6 g/day in 4 oral doses)
Trial: 24576907
Drug: 2-dose (2D)
RxNorm normalized name: Hep A, ped/adol, 2 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose (2D) schedule of HPV-16/18 AS04-adjuvanted vaccine administered at M0,6
Trial: 24576907
Drug: 3-dose (3D)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-dose (3D) schedule of HPV-16/18 AS04-adjuvanted vaccine administered at M0,1,6
Trial: 24576907
Drug: 2-dose (2D)
RxNorm normalized name: Hep A, ped/adol, 2 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose (2D) schedule
Trial: 24576907
Drug: 3-dose (3D)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-dose (3D) schedule
Trial: 22348812
Drug: Air with
RxNorm normalized name: ReliOn True Metrix Air with Bluetooth Self Monitoring Blood Glucose Monitoring System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air with constant flow (1.5 L/min)
Trial: 22348812
Drug: Oxygen with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen with constant flow (1.5 L/min)
Trial: 22348812
Drug: Automated oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated oxygen flow titration
Trial: 20080288
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of periprostatic anesthesia and bilateral pudendal block (group 2)
Trial: 12885708
Drug: NaFeEDTA-fortified fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaFeEDTA-fortified fish sauce (10 g with 5 mg Fe)
Trial: 12885708
Drug: FeSO4-fortified fish
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FeSO4-fortified fish sauce (10 g with 5 mg Fe)
Trial: 12885708
Drug: NaFeEDTA-fortified soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaFeEDTA-fortified soy sauce (10 g with 5 mg Fe)
Trial: 12885708
Drug: FeSO4-fortified soy
RxNorm normalized name: SOY ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FeSO4-fortified soy sauce (10 g with 5 mg Fe)
Trial: 12885708
Drug: Fish sauce
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish sauce effect on iron absorption
Trial: 1770152
Drug: Alprazolam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (mean daily dose: 5.0 ± 2.3 mg)
Trial: 1770152
Drug: Propranolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (mean daily dose: 182.0 ± 60.5 mg)
Trial: 6755764
Drug: Intravenous penbutolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous penbutolol
Trial: 17023203
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g ascorbic acid daily for 4 weeks
Trial: 15010185
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (HED and LED with SFU and CFU)
Trial: 11236112
Drug: Atosiban (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atosiban (n = 363; intravenous (iv) bolus dose of 6.75 mg, then 300 microg/minute iv for 3h and 100 microg/min iv thereafter)
Trial: 11236112
Drug: Beta-agonists (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-agonists (n = 379; ritodrine, salbutamol or terbutaline iv; dose titrated)
Trial: 27261237
Drug: C1 inhibitor
RxNorm normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1 inhibitor concentrate
Trial: 2511744
Drug: Flecainide treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide treatment
Trial: 4948416
Drug: Tetracycline, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline, 2 doses daily for 3 days
Trial: 29520816
Drug: Self-assembling peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-assembling peptide matrix (SAPM) gel, applied ex-office over 1 week
Trial: 26258927
Drug: Telehealth service
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth service delivery model with combined pharmacotherapy and behavior training
Trial: 26258927
Drug: Telepsychiatrists' decision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telepsychiatrists' decision making regarding medication adjustments
Trial: 26258927
Drug: Telepsychiatrists' fidelity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telepsychiatrists' fidelity to chosen algorithms in medication management
Trial: 24898318
Drug: Equine facilitated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equine facilitated learning (EFL) program, 11 weeks, once-weekly 90-min sessions
Trial: 20616418
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (TT) comprising clarithromycin, amoxicillin, omeprazole [n=23]
Trial: 20616418
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g Nigella sativa + 40 mg omeprazole [n=21]
Trial: 20616418
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g Nigella sativa + omeprazole [n=21]
Trial: 20616418
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g Nigella sativa + omeprazole [n=23]
Trial: 18520829
Drug: Topical antiglaucoma
RxNorm normalized name: ANTIGLAUCOMA MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antiglaucoma medications (specific combinations include timolol + dorzolamide, timolol + dorzolamide + pilocarpine)
Trial: 18520829
Drug: Topical antiglaucoma
RxNorm normalized name: ANTIGLAUCOMA MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antiglaucoma medications (timolol + dorzolamide)
Trial: 18520829
Drug: Topical antiglaucoma
RxNorm normalized name: ANTIGLAUCOMA MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antiglaucoma medications (timolol + dorzolamide + pilocarpine)
Trial: 18520829
Drug: Topical antiglaucoma
RxNorm normalized name: ANTIGLAUCOMA MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antiglaucoma medications
Trial: 15784718
Drug: Low GH
RxNorm normalized name: DIMETHICONE 20 mg in 1 g / OCTINOXATE 75 mg in 1 g / OCTISALATE 30 mg in 1 g / OXYBENZONE 30 ug in 1 g TOPICAL STICK [Softlips Marshmallow Ghost]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low GH dose (0.033 mg/kg.d or 0.1 IU/kg.d)
Trial: 15784718
Drug: High GH
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High GH dose (0.067 mg/kg.d or 0.2 IU/kg.d)
Trial: 15784718
Drug: GH (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH (both low and high doses)
Trial: 7955757
Drug: Antigranulocyte antibody
RxNorm normalized name: technetium (99mTc) antigranulocyte antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antigranulocyte antibody imaging
Trial: 3671899
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg/8 h) for 3 days prior to ascent and continued for 15 days at altitude
Trial: 30015697
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy (40% fraction of inspired oxygen, 8 cm H2O CPAP)
Trial: 30015697
Drug: COT (classic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COT (classic oxygen therapy via facemask at 6 L/min)
Trial: 28880902
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% + Clonidine 150μg/ml
Trial: 23239151
Drug: Lapatinib 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1,500 mg + pazopanib 800 mg (Cohort 1)
Trial: 23239151
Drug: Lapatinib 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1,500 mg (Cohort 1)
Trial: 23239151
Drug: Lapatinib 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1,500 mg (Cohort 2)
Trial: 23239151
Drug: Lapatinib 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1,000 mg + pazopanib 400 mg (Cohort 2)
Trial: 23239151
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg (Cohort 2)
Trial: 16706613
Drug: Enfuvirtide (T-20)
RxNorm normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enfuvirtide (T-20) treatment for 48 weeks
Trial: 15841624
Drug: Placebo (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1.0 mL vehicle)
Trial: 11605178
Drug: Paclitaxel 100
RxNorm normalized name: paclitaxel 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel 100 mg/m(2)/wk for 3 weeks + carboplatin (AUC 6) on day 1 every 4 weeks
Trial: 11605178
Drug: Paclitaxel 100
RxNorm normalized name: paclitaxel 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel 100 mg/m(2)/wk for 3 weeks + carboplatin (AUC 2) weekly for 3 weeks
Trial: 11605178
Drug: Paclitaxel 150
RxNorm normalized name: paclitaxel 150 MG per 25 ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel 150 mg/m(2)/wk + carboplatin (AUC 2 per week) during the second 8-week cycle
Trial: 11605178
Drug: Maintenance weekly
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance weekly paclitaxel after initial treatment
Trial: 9663369
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg of cerivastatin sodium once daily after the evening meal for 12 weeks
Trial: 9663369
Drug: 0.15 mg
RxNorm normalized name: iodine 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg of cerivastatin sodium once daily after the evening meal for 12 weeks
Trial: 10480191
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg of cerivastatin sodium
Trial: 9663369
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg and 0.15 mg of cerivastatin sodium combined
Trial: 21350425
Drug: Pantogam activ
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantogam activ (1800 mg/d)
Trial: 12764909
Drug: Yishou Tiaozhi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yishou Tiaozhi Tablet (YSTZT) 4 tablets 3 times a day for 60 days
Trial: 12764909
Drug: Zocor 1
RxNorm normalized name: Zocor 10mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zocor 1 tablet before sleep every evening for 60 days
Trial: 11421893
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (grass pollen-specific allergy vaccine with MPL adjuvant)
Trial: 9240319
Drug: Azathioprine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (1 mg/kg/day)
Trial: 7506322
Drug: Carvedilol (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (25-50 mg o.d.)
Trial: 7506322
Drug: Metoprolol (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100-200 mg o.d.)
Trial: 7506322
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Metoprolol (acute treatment)
Trial: 7506322
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Carvedilol (acute treatment)
Trial: 30178600
Drug: Dapagliflozin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (5 mg/d)
Trial: 31733336
Drug: Twice-daily soak-and-seal
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily soak-and-seal (SS) baths for 15 to 20 minutes (wet method)
Trial: 31733336
Drug: Twice-daily soak-and-seal
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily soak-and-seal (SS) baths (wet method)
Trial: 30326947
Drug: Active ultrasound
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active ultrasound therapy (3 MHz, 0.132 W/cm2, 1.3 W) applied daily for 4 hours over 6 weeks
Trial: 30326947
Drug: Active ultrasound
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active ultrasound therapy
Trial: 30326947
Drug: Active ultrasound
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active ultrasound therapy (in pilot subset)
Trial: 30326947
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (in pilot subset)
Trial: 27517053
Drug: ArmeoSpring training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ArmeoSpring training for 45 minutes daily, 5 days per week for 3 weeks, in addition to conventional rehabilitation
Trial: 22218156
Drug: Strength training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength training with fish oil supplementation (ST90 group) for 90 days (2 g/d)
Trial: 22218156
Drug: Strength training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength training with fish oil supplementation (ST150 group) for 150 days (2 g/d, supplemented 60 days before training)
Trial: 20932341
Drug: Intra-articular BMP-7
RxNorm normalized name: BMP-7
DrugBank: Eptotermin alfa (DB11631)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Intra-articular BMP-7 (1 mg)
Trial: 20932341
Drug: Intra-articular BMP-7
RxNorm normalized name: BMP-7
DrugBank: Eptotermin alfa (DB11631)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Intra-articular BMP-7 (0.1 mg and 0.3 mg)
Trial: 8592597
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg DFO test
Trial: 8592597
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg DFO test
Trial: 8592597
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg DFO test for detecting aluminium toxicity
Trial: 8592597
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg DFO test for detecting aluminium toxicity
Trial: 8592597
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg DFO test for detecting aluminium overload
Trial: 8592597
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg DFO test for detecting aluminium overload
Trial: 30611752
Drug: Caffeine ingestion
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine ingestion (6 mg/kg of body-mass)
Trial: 24252360
Drug: Olaparib, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib, 400 mg orally twice daily until disease progression or drug intolerance
Trial: 22999717
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (12‐month DAPT), n=1058
Trial: 17978849
Drug: Nonsterile gel
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsterile gel
Trial: 12407043
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate 50 mg on days 2-6
Trial: 12407043
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate 50 mg on days 5-9
Trial: 10428533
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (n = 17)
Trial: 1730330
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone agonist (GnRH-a) deslorelin, 300 micrograms daily for 4 months
Trial: 29768149
Drug: Budesonide-formoterol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol) used as needed
Trial: 29768149
Drug: Terbutaline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (0.5 mg) used as needed
Trial: 29768149
Drug: Budesonide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (200 μg) plus terbutaline used as needed
Trial: 22949154
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg per day
Trial: 21129474
Drug: Topical Tangzu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Tangzu Yuyang Ointment (TYO) plus standard wound therapy (SWT)
Trial: 17452166
Drug: Controlled-release paroxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release paroxetine
Trial: 9510396
Drug: Interferon-alpha (IFNalpha)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFNalpha) therapy
Trial: 7357809
Drug: Nefopam 45
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 45 mg
Trial: 359216
Drug: Nefopam 90
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 90 mg
Trial: 6973987
Drug: Propoxyphene 65
RxNorm normalized name: propoxyphene hydrochloride 65 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propoxyphene 65 mg
Trial: 31922998
Drug: Nephrotoxic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nephrotoxic drugs discontinuation
Trial: 31922998
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of radiocontrast agents
Trial: 28329211
Drug: GEN‐003 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEN‐003 (30 µg)
Trial: 28329211
Drug: GEN‐003 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEN‐003 (100 µg)
Trial: 28329211
Drug: GEN‐003 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEN‐003 (10 µg)